Rohto Pharmaceutical Co (4527) AI Stock Analysis

• Market Cap: $492.18B
• Dividend Yield: 1.7%
• Average Volume (3M): 881.18K
• Price to Earnings (P/E): 15.6
• Beta (1Y): 0.58
• Revenue Growth: 13.95%
• EPS Growth: 0.37%
• Country: JP
• Employees: 7,259
• Sector: Healthcare
• Sector Strength: 42
• Industry: Household & Personal Products
• EPS (TTM): 27.38
• Shares Outstanding: 236,178,310
• 10 Day Avg. Volume: 735,980
• 30 Day Avg. Volume: 881,183
• PEG Ratio: 3.20
• Price to Book (P/B): 1.88
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $2,591.11
• Price Target Upside: 22.54% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 6

• Rating: 76 Outperform
• Price Target: ¥2,413.00 ▲(14.12%Upside)

Rohto Pharmaceutical's strong financial performance is the primary driver of its overall score, supported by solid technical indicators and reasonable valuation metrics. The company's robust financials, coupled with positive market momentum, position it well within the industry.

Rohto Pharmaceutical Co Business Overview & Revenue Model

Company Description

Rohto Pharmaceutical Co.,Ltd. manufactures and markets pharmaceutical products, cosmetics, and functional foods worldwide. The company provides eye care products, such as eye drops, care for contact lenses, and eye wash; and facial care products comprising face wash, lotions, and creams. It also offers medicine and medicated products for skin; medicine for internal use, such as digestive and herbal medicines; oral medicines comprising gastrointestinal medicines, herbal medicines, and supplements; non-prescription medicines; and beauty counters that provide beauty and health services. The company was formerly known as Yamada Pharmaceutical and changed its name to Rohto Pharmaceutical Co.,Ltd. in September 1949. Rohto Pharmaceutical Co.,Ltd. was founded in 1899 and is headquartered in Osaka, Japan.

How the Company Makes Money

Rohto Pharmaceutical Co. generates revenue through the sale of its diversified portfolio of over-the-counter medications and consumer healthcare products. The company's primary revenue streams include its eye care products, such as eye drops, and skincare lines, which are popular across various international markets. Additionally, Rohto earns from its pharmaceutical products, including gastrointestinal and anti-inflammatory drugs. Significant partnerships and distribution agreements with retailers and pharmacies enhance its market presence and contribute to its sales. The company's strategic global expansion and innovation in product development also play crucial roles in driving its financial performance.

Rohto Pharmaceutical Co Financial Statement Overview

Summary

Rohto Pharmaceutical exhibits strong financial health with consistent revenue growth, solid profit margins, a robust balance sheet, and effective cash flow management. The company's low debt-to-equity ratio and high equity ratio further indicate financial stability and efficient capital utilization.

Income Statement

Rohto Pharmaceutical has shown a consistent upward trend in revenue growth, with a notable increase of 13.94% in the latest year. Gross profit margin remains strong at 54.88%, and the net profit margin is stable at 10.05%. Despite a slight dip in EBIT margin to 12.46%, the company maintains healthy profitability metrics overall.

Balance Sheet

The company's balance sheet is robust, highlighted by a low debt-to-equity ratio of 0.19, indicating low leverage and financial stability. The equity ratio is healthy at 61.64%, suggesting a strong capital structure. Return on equity stands at 11.92%, showcasing efficient use of equity to generate profit.

Cash Flow

Rohto Pharmaceutical has demonstrated solid cash flow management with a free cash flow growth rate of 9.90%. The operating cash flow to net income ratio is healthy at 1.19, indicating strong cash generation relative to net income. The free cash flow to net income ratio is also favorable at 0.90.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	308.63B	270.84B	238.66B	199.65B	181.05B
Gross Profit	169.38B	157.29B	137.42B	116.49B	106.73B
EBITDA	56.42B	50.40B	41.34B	35.81B	28.61B
Net Income	31.00B	30.94B	26.38B	21.13B	16.74B
Balance Sheet
Total Assets	421.88B	346.18B	309.68B	274.63B	225.79B
Cash, Cash Equivalents and Short-Term Investments	77.16B	89.21B	79.95B	72.79B	52.96B
Total Debt	50.22B	10.49B	11.69B	21.38B	8.10B
Total Liabilities	150.43B	99.14B	94.60B	90.80B	69.18B
Stockholders Equity	260.10B	246.32B	209.57B	178.28B	155.91B
Cash Flow
Free Cash Flow	27.84B	25.33B	21.02B	15.92B	9.70B
Operating Cash Flow	36.92B	34.24B	30.92B	27.25B	20.01B
Investing Cash Flow	-57.55B	-16.32B	-13.18B	-16.41B	-10.24B
Financing Cash Flow	3.70B	-13.78B	-16.20B	3.47B	-2.35B

Rohto Pharmaceutical Co Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2114.50
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4527, the sentiment is Positive. The current price of 2114.5 is above the 20-day moving average (MA) of 2072.08, above the 50-day MA of 2056.06, and below the 200-day MA of 2509.14, indicating a neutral trend. The MACD of 10.95 indicates Negative momentum. The RSI at 57.19 is Neutral, neither overbought nor oversold. The STOCH value of 76.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4527.

Rohto Pharmaceutical Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4527	76 Outperform	$492.18B	15.58	12.05%	1.70%	13.95%	0.37%
Sector *	61 Neutral	HK$17.39B	5.61	-7.44%	3.56%	11.55%	-28.15%
KBYPF	―	$2.68B	37.78	5.17%	1.85%	―	―
KOSCF	―	$2.23B	59.19	2.08%	1.07%	―	―
LIOPF	―	$2.69B	19.24	7.58%	2.19%	―	―
PORBF	―	$1.91B	39.44	4.49%	0.35%	―	―
4911	51 Neutral	¥968.96B	496.62		2.08%	-1.33%	-139.30%

Rohto Pharmaceutical Co Corporate Events

Rohto Pharmaceutical Announces Dividend Increase

Rohto Pharmaceutical Co., Ltd. announced a resolution to pay dividends from retained earnings, with a record date of March 31, 2025. The year-end dividend per share is set at 20 yen, consistent with the most recent forecast, and represents an increase from the previous fiscal year’s 15 yen per share. This decision reflects the company’s strong financial performance and commitment to returning value to shareholders, potentially enhancing its market position and investor confidence.

The most recent analyst rating on (JP:4527) stock is a Buy with a Yen4770.00 price target. To see the full list of analyst forecasts on Rohto Pharmaceutical Co stock, see the JP:4527 Stock Forecast page.

Rohto Pharmaceutical Unveils 2025-2035 Growth Strategy

Rohto Pharmaceutical Co., Ltd. has announced its Medium- to Long-Term Growth Strategy for 2025–2035, focusing on expanding its Self-care and Professional Care domains. The strategy includes global expansion, enhancing technological capabilities, and establishing a medical business foundation. Rohto aims to achieve net sales of 415 billion yen by 2030, with a focus on delivering new value in eye and skincare, advancing research in Phyto-Science, and developing new ophthalmic and regenerative medicine products. The company also plans to increase dividends sustainably while maintaining a strong financial structure.

The most recent analyst rating on (JP:4527) stock is a Buy with a Yen4770.00 price target. To see the full list of analyst forecasts on Rohto Pharmaceutical Co stock, see the JP:4527 Stock Forecast page.

Rohto Pharmaceutical Reports FY2025 Financial Results with Increased Sales and Dividends

Rohto Pharmaceutical Co. reported its consolidated financial results for the fiscal year ending March 31, 2025, showing a 14% increase in net sales to ¥308,625 million. Despite the rise in sales, the company experienced a decline in operating and ordinary income by 2.8% and 4.7% respectively, attributed to various market challenges. The company also announced an increase in annual dividends, reflecting a commitment to shareholder returns. The financial results indicate a strategic focus on expanding its market presence and enhancing corporate value through acquisitions, as evidenced by the inclusion of 46 new subsidiaries.

The most recent analyst rating on (JP:4527) stock is a Buy with a Yen4770.00 price target. To see the full list of analyst forecasts on Rohto Pharmaceutical Co stock, see the JP:4527 Stock Forecast page.

Rohto Pharmaceutical Announces Leadership Changes to Drive Future Growth

Rohto Pharmaceutical Co., Ltd. announced significant leadership changes, including the appointment of Hidetoshi Segi as the new President and Chief Operating Officer, effective after the upcoming shareholders’ meeting. These changes are expected to strengthen the company’s management foundation and drive future growth, with Segi’s leadership focusing on both existing and new business development.